JP2023501445A5 - - Google Patents

Info

Publication number
JP2023501445A5
JP2023501445A5 JP2022526470A JP2022526470A JP2023501445A5 JP 2023501445 A5 JP2023501445 A5 JP 2023501445A5 JP 2022526470 A JP2022526470 A JP 2022526470A JP 2022526470 A JP2022526470 A JP 2022526470A JP 2023501445 A5 JP2023501445 A5 JP 2023501445A5
Authority
JP
Japan
Prior art keywords
cells
dsrna
nucleic acid
stranded nucleic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501445A (ja
JP7899084B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059512 external-priority patent/WO2021092464A2/en
Publication of JP2023501445A publication Critical patent/JP2023501445A/ja
Publication of JP2023501445A5 publication Critical patent/JP2023501445A5/ja
Priority to JP2026063490A priority Critical patent/JP2026119093A/ja
Application granted granted Critical
Publication of JP7899084B2 publication Critical patent/JP7899084B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526470A 2019-11-08 2020-11-06 免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド Active JP7899084B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026063490A JP2026119093A (ja) 2019-11-08 2026-04-08 免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932813P 2019-11-08 2019-11-08
US62/932,813 2019-11-08
PCT/US2020/059512 WO2021092464A2 (en) 2019-11-08 2020-11-06 Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026063490A Division JP2026119093A (ja) 2019-11-08 2026-04-08 免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2023501445A JP2023501445A (ja) 2023-01-18
JP2023501445A5 true JP2023501445A5 (cg-RX-API-DMAC7.html) 2023-11-14
JP7899084B2 JP7899084B2 (ja) 2026-08-03

Family

ID=73699423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526470A Active JP7899084B2 (ja) 2019-11-08 2020-11-06 免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド
JP2026063490A Pending JP2026119093A (ja) 2019-11-08 2026-04-08 免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026063490A Pending JP2026119093A (ja) 2019-11-08 2026-04-08 免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド

Country Status (6)

Country Link
US (1) US20230002766A1 (cg-RX-API-DMAC7.html)
EP (1) EP4055167A2 (cg-RX-API-DMAC7.html)
JP (2) JP7899084B2 (cg-RX-API-DMAC7.html)
CN (1) CN115135765A (cg-RX-API-DMAC7.html)
CA (1) CA3160657A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021092464A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
MY207352A (en) * 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
EP4282963A1 (en) * 2022-05-23 2023-11-29 Eberhard Karls Universität Tübingen, Medizinische Fakultät Nucleic acid modified biological cell with expansion-dependent gene expression
WO2024010524A1 (en) * 2022-07-05 2024-01-11 Agency For Science, Technology And Research Oligonucleotides
CN122477046A (zh) * 2023-11-28 2026-07-28 菲奥医药公司 利用RNAi的增强的组合免疫检查点抑制治疗

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4201860A (en) 1978-05-09 1980-05-06 Bristol-Myers Company Purine derivatives
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
ATE153856T1 (de) 1989-09-08 1997-06-15 Alpha Beta Technology Zusammensetzung zur stimulierung des immunsystems
EP0490995A1 (en) 1989-09-08 1992-06-24 Alpha Beta Technology Method for producing soluble glucans
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2040374C (en) 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
ES2259177T3 (es) 1990-08-13 2006-09-16 Isis Pharmaceuticals, Inc. Oligonucleotidos modificados en el azucar que detectan y modulan la expresion genica.
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
JP3256539B2 (ja) 1990-08-28 2002-02-12 エポック・ファーマシューティカルズ・インコーポレイテッド 連結分子を介する3’―尾分子付オリゴヌクレオチドの固体支持体合成
GB9022560D0 (en) 1990-10-17 1990-11-28 G B Biotechnology Limited Processing of waste
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5525719A (en) 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
US5214135A (en) 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5652359A (en) 1993-12-02 1997-07-29 Epoch Pharmaceuticals, Inc. Oligonucleotides containing n-methyl thiolated bases having antiviral activity
US5646126A (en) 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AUPN398295A0 (en) 1995-07-05 1995-07-27 Carlton And United Breweries Limited Chemical compounds and processes for their production
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US8017742B2 (en) 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
US20040072785A1 (en) 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7098030B2 (en) 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
EP1414865B1 (en) 2000-08-03 2014-04-09 Abac R & D Ag Isolation of glucan particles and uses thereof
US6476003B1 (en) 2000-11-06 2002-11-05 Immusonic, Inc. Method for preparing small particle size glucan in a dry material
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7786094B2 (en) 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
JP2005527639A (ja) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Rna干渉の治療的利用のための方法及び組成物
DE10302421A1 (de) 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
EP1604012A2 (en) 2003-03-05 2005-12-14 The Board of Trustees of The Leland Stanford Junior University METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US20060178327A1 (en) 2003-05-30 2006-08-10 Yeung Wah Hin A Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US20050265957A1 (en) 2004-04-08 2005-12-01 Monahan Sean D Polymerized formamides for use in delivery of compounds to cells
NZ551644A (en) 2004-05-20 2010-06-25 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
AU2006306228A1 (en) 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US20070231392A1 (en) 2006-01-23 2007-10-04 Ernst Wagner CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
WO2007100684A2 (en) * 2006-02-24 2007-09-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
LT2712618T (lt) 2006-06-23 2017-02-27 Engeneic Molecular Delivery Pty Ltd. Vaistų, terapinių nukleorūgščių ir funkcinių nukleorūgščių tikslinis įvedimas į žinduolio ląsteles per nepažeistas žuvusias bakterines ląsteles
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
EP2081949B1 (en) 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20090043367A1 (en) 2007-08-09 2009-02-12 Yitzhak Zilberman Apparatus and methods for removing an electronic implant from a body
CA2713379A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US8575123B2 (en) 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
CN103154246B (zh) * 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
EP2725103A3 (en) * 2011-11-14 2016-01-06 Silenseed Ltd Methods and compositions for treating prostate cancer
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. 癌の免疫療法
CN111201024A (zh) * 2017-08-07 2020-05-26 菲奥医药公司 经化学修饰的寡核苷酸
WO2021138537A1 (en) * 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery

Similar Documents

Publication Publication Date Title
US20230285538A1 (en) Efficacious mrna vaccines
JP2020532955A5 (cg-RX-API-DMAC7.html)
AU2022271376A1 (en) CRISPR/CAS-related methods and compositions for treating herpes simplex virus
JP6295232B2 (ja) 修飾を有するdsRNAによる遺伝子発現の特異的な阻害のための組成物および方法
CA2648585C (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
ES2646097T3 (es) Composición para inhibir la expresión de genes y sus usos
JP2022544412A5 (cg-RX-API-DMAC7.html)
AU2014337506B2 (en) Methods for modulating expression of C9ORF72 antisense transcript
JP2008523094A5 (cg-RX-API-DMAC7.html)
JP2020525011A (ja) 2テイル自己デリバリー型siRNAおよび関連方法
CN103555722A (zh) 利用不对称双链rna特异性抑制kras的方法和组合物
CN105907756A (zh) 延长的dicer酶底物和特异性抑制基因表达的方法
EP4317440A1 (en) Viral vector-based rna delivery system and use thereof
BR112013015816B1 (pt) construção de dna não-codificante, de cadeia aberta linear para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
KR20170120617A (ko) 수포성 표피 박리증 치료를 위한 col7a1 엑손 73에 대응하는 올리고뉴클레오타이드
WO2012144560A1 (ja) 自己ゲル化核酸
WO2017151623A1 (en) Biodegradable activated polymers for therapeutic delivery
JP2024529025A5 (cg-RX-API-DMAC7.html)
CN117343965A (zh) 核酸载体、核酸药及其制备方法和应用
CN105316314B (zh) 一种高纯度的微环dna及其制备方法和应用
JP2014504501A (ja) Hif1αの発現を阻害するsiRNAおよびこれを含む抗癌組成物
CN119040329B (zh) 一种靶向胶质母细胞瘤的siRNA及其应用
KR102685034B1 (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체
CN108251421A (zh) 抑制人和动物中COL1A1基因表达的siRNA、包含其的组合物及其应用
CN114144526A (zh) Eph2a适配体及其用途